- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06746688
O ensaio é o primeiro em humanos, de fase I, aberto, com aumento de dose para avaliar a segurança e tolerabilidade de ES2B-C001 combinado com montanida ou sem montanida, em pacientes com receptor 2 do fator de crescimento epidérmico humano (HER2) Expressando Câncer de Mama Metastático
Um primeiro ensaio em humanos de fase I, aberto, de aumento de dose para avaliar a segurança, tolerabilidade e imunogenicidade/atividade antitumoral preliminar de ES2B-C001 com ou sem montanida em câncer de mama metastático que expressa HER2
The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without [adjuvant], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Graz, Áustria
- Medical University of Graz
-
Linz, Áustria, 4010
- Ordensklinikum Linz GmbH Barmherzige Schwestern
-
Vienna, Áustria, 1090
- Medical University Of Vienna
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients aged ≥18 years at screening visit.
- Diagnosis of HER2-expressing locally advanced, unresectable, or metastatic BC, with HER2 IHC level 1+, 2+ (either FISH negative or positive), or IHC level 3+, after undergoing 2-3 lines of anticancer therapy.
- Life expectancy of at least 3 months.
- ECOG performance status 0-2.
- Patients have adequate bone marrow, kidney, liver, heart, and lung function without clinically significant laboratory parameters as judged by the investigator.
- 12-lead ECG without clinically significant abnormalities and no LBBB, QRS duration >140 ms, or evidence of prior infarction.
- Recovered from side effects, adverse reactions, or adverse events due to prior therapy and/or surgery; any residual toxicities and toxicities related to current anticancer treatment must be ≤ Grade 2, except for alopecia, neuropathy or lymphoedema.
- If female, non-pregnant, postmenopausal, or practicing reliable contraception.
- If male, sterilized or using reliable contraception.
Exclusion Criteria:
- Any planned intravenous chemotherapy regimens or check point inhibitors, or previous therapy with those agents during the past 1 month and the patients are neutropenic. Maintenance therapy with a stable dose of HER2-directed mAbs or treatment with antibody drug conjugates (ADCs) for metastatic BC is allowed at the discretion of the treating physician.
- Symptomatic CNS metastatic disease requiring treatment with high dose steroids (i.e., above 10 mg of prednisone or equivalent) within 14 days prior to first administration of ES2B-C001 (with or without adjuvant).
- Concurrent or recent (within 21 days or 5 half-lives) involvement in any other clinical trial with an investigational drug, device, or other experimental intervention.
- Concomitant severe or uncontrolled underlying medical and/or mental disease unrelated to the tumor, which in the opinion of the investigator is likely to compromise patient safety and affect the trial's outcome.
- Previous documented coronary artery disease or congestive heart failure (>NYHA II).
- Echocardiography with LVEF <50%.
- Uncontrolled hypertension.
- Active, known, or suspected autoimmune disease, except thyroid conditions sufficiently controlled on thyroid hormone therapy, and controlled insulin dependent diabetes.
- Necessity for long-term immunosuppression (≤ 4 mg dexamethasone may be used transiently).
- Systemic infection requiring intravenous antibiotics within 14 days before dosing.
- Chronic use of anti-viral agents, except for human immunodeficiency virus (HIV) or hepatitis B or C virus (HBV, HCV) treatments.
- History of severe hypersensitivity reactions to any of the trial drug components.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Note: Administration of inactivated or recombinant vaccines/killed vaccines are allowed.
- Birthmarks, tattoos, wounds, or skin conditions on deltoid region/buttocks that may obscure the assessment of injection site reactions.
- Female patients who are pregnant, or lactating.
- Any infection (including SARS-CoV-2), that in the opinion of the investigator would, upon inclusion in the trial, lead to potentially harming patients' safety or integrity.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Coorte C1: 50µg ES2B-C001 com [adjuvante]
|
Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations. Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations. |
|
Experimental: Coorte C2: 150µg ES2B-C001 com [adjuvante]
|
Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations. Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations. |
|
Experimental: Cohort C3: 450µg ES2B-C001 com ou sem [adjuvante]
|
Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations. Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To determine the safety, tolerability, maximum tolerated dose (MTD) for ES2B-C001 alone or in combination with [adjuvant].
Prazo: From enrolment to the end of study at week 18
|
|
From enrolment to the end of study at week 18
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Prazo: From enrolment to the end of study at week 18
|
Immunogenicity as humoral immune response: Total anti-HER2 Immunoglobulin G (IgG) and IgG lambda titers in sera by enzyme-linked immunosorbent assay (ELISA). |
From enrolment to the end of study at week 18
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Prazo: From enrolment to the end of study at week 18
|
Percentage of patients with measurable disease at baseline achieving Complete Remission (CR) or Partial Response (PR) according to RECIST 1.1 as assessed by the investigator during routine follow up. |
From enrolment to the end of study at week 18
|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Prazo: From enrolment to the end of study at week 18
|
Percentage of patients with Disease Control Rate (DCR) according to RECIST 1.1 as assessed by the investigator during routine follow up. |
From enrolment to the end of study at week 18
|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Prazo: From enrolment to the end of study at week 18
|
Progression free survival (PFS) in patients with Stable Disease (SD), or PR, at the time of first dosing of ES2B-C001 alone or in combination with [adjuvant] according to RECIST 1.1. |
From enrolment to the end of study at week 18
|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Prazo: From enrolment to the end of study at week 18
|
Overall survival (OS) |
From enrolment to the end of study at week 18
|
|
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Prazo: From enrolment to the end of study at week 18
|
Optionally, other immunogenicity and biomarker readouts: characterization of anti-HER2 immunoglobulins in selected sera, including isotyping (e.g. IgM, IgG and IgG subclasses IgG1-4, IgD, IgE, IgA); analysis of HER2 epitope recognition profiles; cellular immune responses; in vitro cell stimulation assays; and measuring circulating tumor DNA. |
From enrolment to the end of study at week 18
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Thomas K. Jorgensen, ExpreS2ion Biotechnologies
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ES2B-C001-S01
- 2024-516333-12-00 (Ctis)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Within the study de-identified patient data will be shared with
- the operational study team, sponsor, auditor and for reporting of safety events to the regulatory agencies and EC
- Data Monitoring Committees/ or other independent committees during the study
- At the end - data listings are part of the Appendices of the CSR which will be shared to regulatory agencies and EC
Tipo de informação de suporte de compartilhamento de IPD
- SEIVA
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .